Summary: A new study has identified dopamine dysfunction as a previously unrecognized driver of memory loss in Alzheimer’s disease. Focusing on the entorhinal cortex, the brain’s gateway to memory processing, researchers discovered that dopamine levels collapse to less than 20% of normal in Alzheimer’s models, causing memory circuits to fail.
Remarkably, by restoring dopamine signaling via optogenetics or the standard Parkinson’s drug Levodopa (L-DOPA), scientists successfully normalized neural activity and completely reversed cognitive decline, unlocking a promising new frontier for memory restoration.
Key Facts
- The Entorhinal Collapse: In a mouse model of Alzheimer’s disease, dopamine levels within the entorhinal cortex plummeted to less than 20% of baseline levels, resulting in a total failure of memory-encoding neurons to respond to stimuli.
- Associative Memory Failure: This severe neurochemical drop was directly linked to a loss of associative memory, demonstrated by an inability to complete odor-based learning tasks.
- Bypassing the Plaques: Traditional treatments targeting amyloid-b and tau proteins have yielded limited success in bringing back cognitive function; this new approach targets the active functional circuitry of memory instead of just clearable pathology.
- Dual Restoration Pathways: Memory function was successfully rescued using two independent methods: optogenetics (using light to stimulate specific dopamine neurons) and Levodopa (L-DOPA), a widely available pharmaceutical compound traditionally reserved for Parkinson’s disease.
Source: Tohoku University
Imagine if patients with Alzheimer’s could have their memories restored. Such a future may seem like a pipe dream, but a new study by researchers at Tohoku University, in collaboration with the University of California, Irvine, has identified dopamine dysfunction as a previously unrecognized mechanism underlying memory impairment, unlocking a potential therapeutic means of reversing cognitive decline.
Details of the breakthrough were published in the journal Nature Neuroscience on April 23, 2026.
Whether a certain smell brings you back to a place from your youth or a song on the radio makes you recall an event from the past, memory formation is often associated with experiences. While scientists have long known that the medial temporal lobe lies at the heart of memory formation, they have struggled to understand the neural changes that disrupt this process in Alzheimer’s disease.
To investigate this, a research team led by Kei Igarashi, a Distinguished Professor at Tohoku University School of Medicine, focused on the entorhinal cortex, a brain region that serves as a gateway to the hippocampus and is essential for memory processing.
Building on previous findings that dopamine is critical for memory formation in this region, the team investigated whether dopamine dysfunction contributes to memory deficits associated with Alzheimer’s disease.
Using a mouse model of Alzheimer’s disease, the researchers found that dopamine levels in the entorhinal cortex were dramatically reduced to less than 20% of normal levels.
This reduction was accompanied by severe impairments in associative memory, which were observed during odor-based learning tasks. Electrophysiological analyses further revealed that neurons in this region failed to respond appropriately to stimuli that should be encoded as memories.
Igarashi and his team then turned to the question of whether dopamine could rescue memory function by increasing dopamine levels in the entorhinal cortex using optogenetic techniques.
They found that this intervention restored the mice’s ability to form memories, while administering Levodopa — a drug widely used to treat Parkinson’s disease — also normalized neural activity and improved memory performance.
“We revealed that dopamine dysfunction plays a central role in memory impairment in Alzheimer’s disease,” explained Kei Igarashi. “The discovery was unexpected, but it opens new possibilities for therapeutic intervention for the millions of Alzheimer’s disease sufferers around the world.”
Current treatments targeting amyloid-β and tau proteins have shown limited success in restoring cognitive function. The findings from this study show that dopamine is a critical component of memory circuits, and that targeted interventions to restore dopamine signaling may help slow or reverse cognitive decline.
Dopamine-based therapies could serve as a promising new direction for treatment, meaning the recovery of lost memories may not be such a pipe dream after all.
Key Questions Answered:
A: Parkinson’s is famously caused by a lack of dopamine in the brain’s movement centers, which is why Levodopa is used to replenish it. This study revealed a hidden parallel: Alzheimer’s quietly destroys dopamine levels in the brain’s memory centers (the entorhinal cortex) down to less than 20%. By introducing Levodopa, researchers refueled those starved memory circuits, normalizing neural activity and bringing back lost cognitive function.
A: Think of the entorhinal cortex as the grand entrance and security gate to the hippocampus, the brain’s primary memory machine. If the entorhinal cortex doesn’t have enough dopamine, its neurons refuse to fire correctly, essentially locking the gate. No matter how functional the rest of the brain is, experiences can’t cross over to become lasting memories.
A: While this study was conducted on animal models, the results are a monumental paradigm shift. Current mainstream drugs focus on clearing away protein “clutter” (amyloid and tau) but fail to fix the broken communication lines left behind. This discovery proves that targeting dopamine signaling can directly reboot the memory circuits themselves, meaning memory recovery may actually be achievable.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this Alzheimer’s disease and neuropharmacology research news
Author: Public Relations Office
Source: Tohoku University
Contact: Public Relations Office – Tohoku University
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Early dopamine disruption in the entorhinal cortex of a knock-in model of Alzheimer’s disease” by Tatsuki Nakagawa, Jiayun L. Xie, Kiwon Park, Kai Cao, Marjan Savadkohighodjanaki, Yutian J. Zhang, Heechul Jun, Ayana Ichii, Jason Y. Lee, Shogo Soma, Yasmeen K. Medhat, Takaomi C. Saido & Kei M. Igarashi. Nature Neuroscience
DOI:10.1038/s41593-026-02260-w
Abstract
Early dopamine disruption in the entorhinal cortex of a knock-in model of Alzheimer’s disease
The entorhinal cortex is a critical brain area for memory formation, while also the region exhibiting the earliest histological and functional alterations in Alzheimer’s disease (AD).
The entorhinal cortex therefore has been long hypothesized as one of the originating brain areas of AD pathophysiology, although circuit mechanisms causing its selective vulnerability remain poorly understood.
Here we show that dopamine neurons projecting their axons to the lateral entorhinal cortex (LEC), critical for memory formation in healthy brains, become dysfunctional from the early pathological stage and cause associative memory impairments in amyloid precursor protein knock-in mice.
Dopamine dysfunction led to the disruption of associative memory encoding of LEC layer 2/3. Optogenetic reactivation of LEC dopamine fibers rescued associative learning behavior. L-DOPA treatment restored memory encoding of LEC neurons and associative memory of amyloid precursor protein knock-in mice.
These results suggest early dysfunction of LEC-projecting dopamine neurons underlie memory impairment in AD from early stages, pointing to a need for clinical investigation of LEC dopamine in patients with AD.
